Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) CEO David James Lennon sold 9,689 shares of the company’s stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $1.94, for a total transaction of $18,796.66. Following the completion of the transaction, the chief executive officer now owns 22,869 shares in the company, valued at approximately $44,365.86. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Aadi Bioscience Stock Up 1.0 %
NASDAQ AADI opened at $1.94 on Friday. The firm has a market capitalization of $47.63 million, a P/E ratio of -0.76 and a beta of 0.70. The company has a 50-day moving average price of $1.70 and a 200-day moving average price of $1.77. Aadi Bioscience, Inc. has a 52 week low of $1.21 and a 52 week high of $5.70.
Aadi Bioscience (NASDAQ:AADI – Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.17. Aadi Bioscience had a negative net margin of 274.77% and a negative return on equity of 66.67%. The business had revenue of $6.18 million for the quarter, compared to the consensus estimate of $6.33 million. During the same period last year, the firm earned ($0.67) earnings per share. As a group, equities research analysts anticipate that Aadi Bioscience, Inc. will post -2.02 EPS for the current year.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on AADI
Hedge Funds Weigh In On Aadi Bioscience
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Marquette Asset Management LLC bought a new position in shares of Aadi Bioscience in the first quarter worth about $135,000. Acuitas Investments LLC raised its stake in Aadi Bioscience by 10.8% during the 2nd quarter. Acuitas Investments LLC now owns 352,483 shares of the company’s stock worth $515,000 after acquiring an additional 34,344 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Aadi Bioscience during the second quarter valued at approximately $37,000. 52.08% of the stock is currently owned by hedge funds and other institutional investors.
About Aadi Bioscience
Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.
See Also
- Five stocks we like better than Aadi Bioscience
- Top Stocks Investing in 5G Technology
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- How to Invest in Blue Chip Stocks
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- The 3 Best Blue-Chip Stocks to Buy Now
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.